8-K: Corcept Therapeutics' New Drug Application for Relacorilant Filed by FDA, Target Action Date Set

The FDA has filed Corcept Therapeutics' New Drug Application for relacorilant, a selective cortisol modulator, for the treatment of endogenous hypercortisolism (Cushing's syndrome).

Summary

• Corcept Therapeutics announced that the FDA has filed its New Drug Application (NDA) for relacorilant to treat patients with Cushing's syndrome.
• The NDA is based on positive results from the GRACE trial, confirmatory evidence from the Phase 3 GRADIENT trial, a long-term extension trial, and a Phase 2 trial.
• Patients in these trials experienced improvements in hypercortisolism signs and symptoms and relacorilant was well tolerated.
• Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia, or QT prolongation.
• The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the FDA filing of the NDA, positive clinical trial results, and the potential for relacorilant to become a new standard of care. However, there are inherent risks associated with regulatory approval and commercialization.

Positives

• The FDA filing of the NDA for relacorilant is a significant milestone for Corcept Therapeutics.
• Clinical trial data supports the efficacy and safety of relacorilant in treating Cushing's syndrome.
• Relacorilant has the potential to become a new standard of care for patients with hypercortisolism.
• Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome.

Risks

• The FDA may not approve the NDA for relacorilant.
• Relacorilant may not be accepted by physicians and patients.
• The commercial prospects for relacorilant are uncertain.
• Clinical trials may not continue to be successful.

Future Outlook

Corcept is optimistic about the potential for relacorilant to become a new standard of care for patients with Cushing's syndrome and is studying relacorilant in other serious disorders, including ovarian and prostate cancer.

Management Comments

• Joseph Belanoff, M.D., Corcept's Chief Executive Officer, stated that the FDA's acceptance of the NDA takes them another step closer to bringing relacorilant to patients with hypercortisolism.
• He also noted that relacorilant's combination of efficacy and safety gives it the potential to become the new standard of care for patients struggling with the devastating impact of this disease.

Industry Context

This announcement positions Corcept Therapeutics to potentially compete with existing treatments for Cushing's syndrome, such as Korlym (also developed by Corcept) and other medications that address the symptoms of the disease. Relacorilant's selective cortisol modulation and favorable safety profile could provide a competitive advantage.

Comparison to Industry Standards

• Korlym, also by Corcept, is an existing treatment for Cushing's, but relacorilant aims to improve upon it with a more selective mechanism and fewer side effects.
• Other treatments, like ketoconazole and metyrapone, are used off-label or have significant side effect profiles, making relacorilant a potentially more attractive option if approved.
• Companies like Novartis (Isturisa) also have treatments for Cushing's, but relacorilant's unique profile could allow it to capture a significant market share.

Stakeholder Impact

• Shareholders: Positive news as it represents progress in the development of a potential new treatment.
• Patients: Potential access to a new and potentially improved treatment option for Cushing's syndrome.
• Employees: Positive impact on morale and job security due to company progress.
• Physicians: A potentially new tool in their arsenal for treating Cushing's syndrome.

Next Steps

• The FDA will review the NDA for relacorilant.
• The FDA will make a decision on the NDA by the PDUFA target action date of December 30, 2025.
• Corcept will continue to study relacorilant in other serious disorders.

Key Dates